What it's for (Indications)
- Naphazoline hydrochloride and pheniramine maleate ophthalmic solution is indicated for the temporary relief of ocular symptoms associated with allergic conjunctivitis, such as redness, itching, and irritation of the eyes.
- This combination therapy targets both the vascular congestion and the histamine-mediated allergic response, providing comprehensive relief.
- It is designed for short-term use in managing acute episodes of ocular allergy, offering symptomatic improvement to patients experiencing discomfort from common environmental allergens.
- Healthcare professionals should advise patients on the appropriate duration of use to prevent potential complications, ensuring that the treatment aligns with the transient nature of mild to moderate allergic eye conditions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults and children 6 years of age and older, the recommended dosage is one or two drops instilled into the affected eye(s) up to four times daily, as needed. It is crucial to emphasize that this medication should not be used for more than 3 to 4 consecutive days without consulting a healthcare professional. Prolonged use can lead to rebound conjunctival hyperemia, which may exacerbate the initial symptoms of redness and irritation upon discontinuation. Patients should be instructed on proper instillation technique to minimize contamination and ensure effective delivery of the medication to the ocular surface, avoiding contact of the dropper tip with the eye or any other surface. Contact lenses should be removed prior to application and can be reinserted 15 minutes after administration to prevent absorption of the preservative by the lens material. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with naphazoline and pheniramine ophthalmic solution include transient stinging or burning upon instillation, blurred vision, pupil dilation (mydriasis), and increased intraocular pressure.
- Less frequently, patients may experience local irritation, reactive hyperemia (rebound redness, especially with overuse), or punctate keratitis.
- Due to potential systemic absorption, albeit usually minimal, systemic adverse effects can occur, particularly in susceptible individuals or with excessive use.
- These may include headache, drowsiness, dizziness, nervousness, tremors, palpitations, tachycardia, and hypertension.
- Patients should be advised to discontinue use and seek medical attention if any severe or persistent adverse reactions occur, or if symptoms worsen or persist beyond the recommended treatment duration.
Serious Warnings
- Black Box Warning: Naphazoline + Pheniramine ophthalmic solutions do not have a formal FDA-mandated Black Box Warning. However, due to the potential for serious adverse effects, particularly with misuse, prolonged use, or in susceptible patient populations, significant safety information must be conveyed. Therefore, a 'Serious Warnings' section is provided herein to highlight critical safety considerations. **Serious Warnings:** 1. **Risk of Rebound Conjunctival Hyperemia:** Prolonged or excessive use (typically beyond 3 to 4 days) can lead to rebound vasodilation, resulting in exacerbated ocular redness and irritation upon discontinuation. Patients should be strongly advised against exceeding the recommended duration of use to avoid this dependency cycle and potential worsening of symptoms. 2. **Systemic Absorption and Cardiovascular/CNS Effects:** Although primarily acting topically, systemic absorption can occur, particularly in children or patients with compromised ocular surface integrity. This may lead to clinically significant systemic effects such as hypertension, tachycardia, arrhythmias, nervousness, dizziness, tremor, or headache. Use with extreme caution in patients with cardiovascular disease, hypertension, diabetes, hyperthyroidism, or in those taking systemic vasoconstrictors or MAO inhibitors, as the systemic effects of naphazoline can be potentiated. 3. **Precipitation of Angle-Closure Glaucoma:** The vasoconstrictor naphazoline can induce pupillary dilation (mydriasis), which may precipitate an acute attack of angle-closure glaucoma in individuals with a narrow anterior chamber angle. This medication is strictly contraindicated in patients with narrow-angle glaucoma due to the risk of significant vision loss. 4. **Use in Children:** Special caution is required when administering to young children due to increased susceptibility to systemic absorption and severe adverse reactions, including CNS depression and cardiovascular events. It is generally not recommended for children under 6 years of age without explicit medical supervision. 5. **Contact Lens Use:** Patients should remove soft contact lenses before instillation and wait at least 15 minutes before reinserting them, as preservatives in the solution may be absorbed by the lenses, leading to irritation or discoloration. These warnings underscore the importance of proper patient selection, adherence to dosage instructions, and careful monitoring for adverse effects to ensure patient safety.
- This ophthalmic combination product carries several important warnings that patients and healthcare providers must consider.
- A primary concern is the potential for **rebound conjunctival hyperemia** with prolonged or excessive use (typically more than 3-4 days).
- This phenomenon can lead to worsening redness upon discontinuation, trapping patients in a cycle of dependency.
- Furthermore, systemic absorption, though generally low, can occur and may precipitate **cardiovascular effects** such as hypertension, tachycardia, or arrhythmias, particularly in patients with pre-existing cardiovascular disease, hyperthyroidism, or diabetes, or in young children.
- The vasoconstrictive action of naphazoline can also induce **angle-closure glaucoma** in individuals with a narrow anterior chamber angle, due to pupillary dilation.
- Patients should be advised against using this medication while wearing soft contact lenses and to remove them before application, waiting at least 15 minutes before reinsertion.
- Discontinue use and consult a physician if eye pain, vision changes, persistent redness or irritation, or if symptoms worsen or persist for more than 72 hours.
- This product is intended for temporary relief only.
How it Works (Mechanism of Action)
The therapeutic efficacy of naphazoline and pheniramine ophthalmic solution stems from the synergistic actions of its two active components. **Naphazoline hydrochloride** is a sympathomimetic amine that acts as an alpha-adrenergic agonist. Upon topical application to the eye, it causes vasoconstriction of the conjunctival blood vessels, primarily the arterioles. This action leads to a significant reduction in ocular redness and swelling (edema), thereby alleviating the congested appearance of allergic conjunctivitis. **Pheniramine maleate** is an antihistamine, specifically an H1-receptor antagonist. In allergic reactions, histamine is released and binds to H1 receptors, causing symptoms such as itching, tearing, and vasodilation. Pheniramine works by blocking these histamine H1 receptors, thus preventing or relieving the histamine-mediated symptoms of allergic conjunctivitis. The combination provides a dual approach to managing allergic eye symptoms by addressing both the vascular congestion and the allergic inflammatory cascade, offering comprehensive symptomatic relief.
Commercial Brands (Alternatives)
No other brands found for this formula.